SAGENT PHARMACEUTICALS - Trademark Details
Status: 606 - Abandoned - No Statement Of Use Filed
Serial Number
78867342
Word Mark
SAGENT PHARMACEUTICALS
Status
606 - Abandoned - No Statement Of Use Filed
Status Date
2011-04-30
Filing Date
2006-04-21
Mark Drawing
4000 - Standard character mark
Typeset
Published for Opposition Date
2008-02-05
Attorney Name
Law Office Assigned Location Code
L40
Employee Name
BROWNE, DAYNA J
Statements
Disclaimer with Predetermined Text
"PHARMACEUTICALS"
Goods and Services
Pharmaceuticals, namely, alkalizing agents, analgesics and anesthetics, antacids, anticholinergics, antihistamines, anti-inflammatory agents, anticonvulsants, antidotes, antiemetics, antipsychotics, anxiolytics, blood modifiers, bronchodialators, diuretics, hormones, diluents, electrolytes, vitamins, oncolytics, immunosuppressive agents, transplantation agents, imaging agents, and sensitizing agents for chemotherapy-resistant tumors; Pre-filled syringes sold filled with alkalizing agents; pre-filled syringes sold filled with analgesics; pre-filled syringes sold filled with anesthetics; pre-filled syringes sold filled with antacids; pre-filled syringes sold filled with anticholinergics; pre-filled syringes sold filled with antihistamines; pre-filled syringes sold filled with anti-infectives; pre-filled syringes sold filled with anti-inflammatory agents; pre-filled syringes sold filled with anticonvulsants; pre-filled syringes sold filled with antidotes; pre-filled syringes sold filled with antiemetics; pre-filled syringes sold filled with antipsychotics; pre-filled syringes sold filled with anxiolytics; pre-filled syringes sold filled with blood modifiers; pre-filled syringes sold filled with bronchodialators; pre-filled syringes sold filled with cardiovasculars; pre-filled syringes sold filled with diuretics; pre-filled syringes sold filled with hormones; pre-filled syringes sold filled with diluents; pre-filled syringes sold filled with electrolytes; pre-filled syringes sold filled with vitamins; pre-filled syringes sold filled with oncolytics; pre-filled syringes sold filled with immunosuppressive agents; pre-filled syringes sold filled with transplantation agents; pre-filled syringes sold filled with imaging agents; pre-filled syringes sold filled with vascular targeting agents; pre-filled syringes sold filled with sensitizing agents for chemotherapy-resistant tumors; Safety syringe devices sold filled with alkalizing agents; safety syringe devices sold filled with analgesics; safety syringe devices sold filled with anesthetics; safety syringe devices sold filled with antacids; safety syringe devices sold filled with anticholinergics; safety syringe devices sold filled with antihistamines; safety syringe devices sold filled with anti-infectives; safety syringe devices sold filled with anti-inflammatory agents; safety syringe devices sold filled with anticonvulsants; safety syringe devices sold filled with antidotes; safety syringe devices sold filled with antiemetics; safety syringe devices sold filled with antipsychotics; safety syringe devices sold filled with anxiolytics; safety syringe devices sold filled with blood modifiers; safety syringe devices sold filled with bronchodialators; safety syringe devices sold filled with cardiovasculars; safety syringe devices sold filled with diuretics; safety syringe devices sold filled with hormones; safety syringe devices sold filled with diluents; safety syringe devices sold filled with electrolytes; safety syringe devices sold filled with vitamins; safety syringe devices sold filled with oncolytics; safety syringe devices sold filled with immunosuppressive agents; safety syringe devices sold filled with transplantation agents; safety syringe devices sold filled with imaging agents; safety syringe devices sold filled with vascular targeting agents; safety syringe devices sold filled with sensitizing agents for chemotherapy-resistant tumors; Pharmaceuticals for treatment of cancer; pharmaceuticals to treat vascular diseases; Drug delivery systems sold as an integral component of drugs, namely, intradermal injection system for injection of anesthetics; Injectable drugs and therapeutic solutions for the treatment of cancer injectable drugs and therapeutic solutions for the treatment of psychotic disorders; injectable drugs and therapeutic solutions for the treatment of pain; injectable drugs and therapeutic solutions for the treatment of kidney disease; injectable drugs and therapeutic solutions for the treatment of hormonal imbalances; injectable drugs and therapeutic solutions for the treatment of vitamin deficiencies; injectable drugs and therapeutic solutions for the treatment of electrolyte deficiencies; injectable drugs and therapeutic solutions for the treatment of heartburn; injectable drugs and therapeutic solutions for the treatment of anxiety; injectable drugs and therapeutic solutions for immunosuppression; injectable drugs and therapeutic solutions for imaging; injectable drugs and therapeutic solutions for the treatment of seizures; Injectable drugs and therapeutic solutions for the treatment of cancer and vascular diseases sold in kits comprising pre-filled IV bags with devices for intravenous administration, namely, transfer pins, vials, needles, and adaptors; injectable drugs and therapeutic solutions for the treatment of psychotic disorders sold in kits comprising pre-filled IV bags with devices for intravenous administration, namely, transfer pins, vials, needles, and adaptors; injectable drugs and therapeutic solutions for the treatment of pain sold in kits comprising pre-filled IV bags with devices for intravenous administration, namely, transfer pins, vials, needles, and adaptors; injectable drugs and therapeutic solutions for the treatment of allergies sold in kits comprising pre-filled IV bags with devices for intravenous administration, namely, transfer pins, vials, needles, and adaptors; injectable drugs and therapeutic solutions for the treatment of infections sold in kits comprising pre-filled IV bags with devices for intravenous administration, namely, transfer pins, vials, needles, and adaptors; injectable drugs and therapeutic solutions for the treatment of cardiovascular disease sold in kits comprising pre-filled IV bags with devices for intravenous administration, namely, transfer pins, vials, needles, and adaptors; injectable drugs and therapeutic solutions for the treatment of kidney disease sold in kits comprising pre-filled IV bags with devices for intravenous administration, namely, transfer pins, vials, needles, and adaptors; injectable drugs and therapeutic solutions for the treatment of hormonal imbalances sold in kits comprising pre-filled IV bags with devices for intravenous administration, namely, transfer pins, vials, needles, and adaptors; injectable drugs and therapeutic solutions for the treatment of vitamin deficiencies sold in kits comprising pre-filled IV bags with devices for intravenous administration, namely, transfer pins, vials, needles, and adaptors; injectable drugs and therapeutic solutions for the treatment of electrolyte deficiencies sold in kits comprising pre-filled IV bags with devices for intravenous administration, namely, transfer pins, vials, needles, and adaptors; injectable drugs and therapeutic solutions for the treatment of heartburn sold in kits comprising pre-filled IV bags with devices for intravenous administration, namely, transfer pins, vials, needles, and adaptors; injectable drugs and therapeutic solutions for the treatment of anxiety sold in kits comprising pre-filled IV bags with devices for intravenous administration, namely, transfer pins, vials, needles, and adaptors; injectable drugs and therapeutic solutions for immunosuppression sold in kits comprising pre-filled IV bags with devices for intravenous administration, namely, transfer pins, vials, needles, and adaptors; injectable drugs and therapeutic solutions for imaging sold in kits comprising pre-filled IV bags with devices for intravenous administration, namely, transfer pins, vials, needles, and adaptors; injectable drugs and therapeutic solutions for the treatment of seizures sold in kits comprising pre-filled IV bags with devices for intravenous administration, namely, transfer pins, vials, needles, and adaptors
Classification Information
International Class
005 - Pharmaceutical, veterinary and sanitary preparations; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides. - Pharmaceutical, veterinary and sanitary preparations; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes
006, 018, 044, 046, 051, 052
Class Status Code
6 - Active
Class Status Date
2006-04-27
Primary Code
005
Correspondences
Name
Bradley W. Crawford
Address
Please log in with your Justia account to see this address.
Prior Registrations
Relationship Type | Reel Number |
Continuity Child | 78981049 |
Trademark Events
Event Date | Event Description |
2006-04-27 | NEW APPLICATION ENTERED IN TRAM |
2006-09-25 | ASSIGNED TO EXAMINER |
2006-09-27 | NON-FINAL ACTION WRITTEN |
2006-09-27 | NON-FINAL ACTION E-MAILED |
2007-04-25 | ABANDONMENT - FAILURE TO RESPOND OR LATE RESPONSE |
2007-04-25 | ABANDONMENT NOTICE MAILED - FAILURE TO RESPOND |
2007-05-07 | PAPER RECEIVED |
2007-05-07 | PETITION TO REVIVE-RECEIVED |
2007-06-07 | TEAS REVOKE/APPOINT ATTORNEY RECEIVED |
2007-06-07 | ATTORNEY REVOKED AND/OR APPOINTED |
2007-06-11 | PETITION GRANTED - REMAIL OFFICE ACTION |
2007-06-12 | NON-FINAL ACTION WRITTEN |
2007-06-12 | NON-FINAL ACTION E-MAILED |
2007-06-12 | NOTIFICATION OF NON-FINAL ACTION E-MAILED |
2007-07-24 | TEAS RESPONSE TO OFFICE ACTION RECEIVED |
2007-07-24 | CORRESPONDENCE RECEIVED IN LAW OFFICE |
2007-07-24 | TEAS/EMAIL CORRESPONDENCE ENTERED |
2007-08-14 | NON-FINAL ACTION WRITTEN |
2007-08-14 | NON-FINAL ACTION E-MAILED |
2007-08-14 | NOTIFICATION OF NON-FINAL ACTION E-MAILED |
2007-09-28 | TEAS RESPONSE TO OFFICE ACTION RECEIVED |
2007-09-28 | CORRESPONDENCE RECEIVED IN LAW OFFICE |
2007-09-29 | TEAS/EMAIL CORRESPONDENCE ENTERED |
2007-10-26 | EXAMINERS AMENDMENT -WRITTEN |
2007-10-26 | EXAMINERS AMENDMENT E-MAILED |
2007-10-26 | NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED |
2007-10-26 | EXAMINER'S AMENDMENT ENTERED |
2007-10-26 | APPROVED FOR PUB - PRINCIPAL REGISTER |
2007-12-01 | ASSIGNED TO LIE |
2007-12-01 | LAW OFFICE PUBLICATION REVIEW COMPLETED |
2007-12-14 | WITHDRAWN FROM PUB - OG REVIEW QUERY |
2008-01-16 | NOTICE OF PUBLICATION |
2008-02-05 | PUBLISHED FOR OPPOSITION |
2008-04-29 | NOA MAILED - SOU REQUIRED FROM APPLICANT |
2008-10-29 | TEAS EXTENSION RECEIVED |
2008-10-29 | EXTENSION 1 FILED |
2008-10-29 | EXTENSION 1 GRANTED |
2009-03-04 | AUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP |
2009-03-06 | TEAS STATEMENT OF USE RECEIVED |
2009-03-06 | TEAS EXTENSION RECEIVED |
2009-03-06 | TEAS REQUEST TO DIVIDE RECEIVED |
2009-03-27 | CASE ASSIGNED TO INTENT TO USE PARALEGAL |
2009-03-06 | EXTENSION 2 FILED |
2009-03-27 | EXTENSION 2 GRANTED |
2009-03-06 | DIVISIONAL REQUEST RECEIVED |
2009-03-27 | DIVISIONAL PROCESSING COMPLETE |
2009-10-29 | TEAS EXTENSION RECEIVED |
2009-10-29 | EXTENSION 3 FILED |
2009-11-02 | EXTENSION 3 GRANTED |
2010-04-15 | TEAS EXTENSION RECEIVED |
2010-04-15 | EXTENSION 4 FILED |
2010-04-26 | EXTENSION 4 GRANTED |
2010-04-27 | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED |
2010-10-14 | TEAS EXTENSION RECEIVED |
2010-10-14 | EXTENSION 5 FILED |
2010-10-21 | EXTENSION 5 GRANTED |
2010-10-22 | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED |
2012-10-09 | ABANDONMENT - NO USE STATEMENT FILED |
2012-10-09 | ABANDONMENT NOTICE MAILED - NO USE STATEMENT FILED |